Missak Haigentz
Rutgers Cancer Institute of New Jersey
- 19
195 Little Albany Street
New Brunswick, New Jersey 08903
United States
Map It
Dr. Haigentz, chief, Thoracic and Head & Neck Medical Oncology at the Rutgers Cancer Institute of New Jersey, is recognized nationally and internationally as an expert in cancers of the head and neck, including thyroid cancers, and in lung cancers. Dr. Haigentz has particular expertise in the design and conduct of innovative clinical trials to improve the lives of cancer patients, and he has led several multicenter and national clinical trials. His research has received funding from the National Institutes of Health and the Conquer Cancer Foundation of the American Society of Clinical Oncology. He is the author of numerous peer-reviewed manuscripts, review articles and book chapters, and he has served on the editorial board of the Journal of Clinical Oncology. He has held several leadership roles, including service as president of the New York Head and Neck Society (2014-2015).
Throughout his career, Dr. Haigentz has taken pride in providing compassionate and personalized cancer care, with expertise in bringing high priority cancer research to people in their communities. His notable contributions in National Cancer Trials operations have included directorship of the clinical trials office of the NCI-dsignated Albert Einstein Cancer Center, and most recently as the founding principal investigator for the the first NCI Community Oncology Research Program (NCORP) site based in New Jersey.
His clinical and research practice is focused on thoracic and head & neck cancers.
- NRG HN005: A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer NCT03952585
- EA3161: A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA NCT03811015
- NRG HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) NCT02135042
- ATATcH: Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers NCT05358548
- LEAP-009: A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) NCT04428151